bispecific tcell engagers bites class artificial bispecific monoclonal antibodies investigated use anticancer drugs direct hosts immune system specifically cells cytotoxic activity cancer cells bite registered trademark micromet ag fully owned subsidiary amgen bites fusion proteins consisting two singlechain variable fragments scfvs different antibodies amino acid sequences four different genes single peptide chain kilodaltons one scfvs binds cells via receptor tumor cell via tumor specific like bispecific antibodies unlike ordinary monoclonal antibodies bites form link cells tumor cells causes cells exert cytotoxic activity tumor cells producing proteins like perforin granzymes independently presence mhc costimulatory molecules proteins enter tumor cells initiate cells action mimics physiological processes observed cell attacks tumor several bites currently preclinical clinical trials assess therapeutic efficacy safety blinatumomab links cells receptors found surface b cells food drug administration us european medicines agency approved therapy adults philadelphia chromosomenegative relapsed refractory acute lymphoblastic bispecific tcell engager approved medical use canada march united states june european union july bispecifically binds engage tcells mosunetuzumab approved medical use european union june solitomab links cells epcam antigen expressed colon gastric prostate ovarian lung pancreatic clinical trials january us fda approved tebentafusp bite targeting peptide adult patients unresectable metastatic uveal utilizing technology melanoma mcsp specific bites acute myeloid leukemia specific bites research area another avenue novel anticancer therapies reengineering currently used conventional antibodies like trastuzumab targeting cetuximab panitumumab targeting egf receptor using bite bites developed httpsenwikipediaorgwikibispecifictcellengager